Glenmark Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Glenmark Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 113% bzw. 10.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 111.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12% betragen.

Wichtige Informationen

94.1%

Wachstumsrate der Gewinne

87.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.5%
Wachstumsrate der Einnahmen	12.5%
Zukünftige Eigenkapitalrendite	18.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	16 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05

If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Mar 25

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Jan 18

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Dec 13

Gewinn- und Umsatzwachstumsprognosen

NSEI:GLENMARK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	174,569	21,289	17,528	27,588	2
3/31/2026	154,266	16,452	11,586	18,153	11
3/31/2025	137,990	13,035	1,586	8,957	11
3/31/2024	118,131	-18,990	-11,638	-2,654	N/A
12/31/2023	131,575	-7,640	N/A	N/A	N/A
9/30/2023	137,510	-1,263	302	7,192	N/A
6/30/2023	136,144	2,546	N/A	N/A	N/A
3/31/2023	129,901	2,972	176	6,254	N/A
12/31/2022	126,355	8,811	N/A	N/A	N/A
9/30/2022	123,451	8,305	-21	7,689	N/A
6/30/2022	121,173	8,277	N/A	N/A	N/A
3/31/2022	123,049	9,417	3,185	11,087	N/A
12/31/2021	122,103	10,202	N/A	N/A	N/A
9/30/2021	118,248	10,464	5,411	12,490	N/A
6/30/2021	116,144	10,226	N/A	N/A	N/A
3/31/2021	109,439	9,700	3,565	11,312	N/A
12/31/2020	107,778	9,565	N/A	N/A	N/A
9/30/2020	107,445	8,992	3,945	12,296	N/A
6/30/2020	106,629	9,207	N/A	N/A	N/A
3/31/2020	106,573	7,760	4,610	13,924	N/A
12/31/2019	104,370	7,173	N/A	N/A	N/A
9/30/2019	102,564	6,428	1,271	13,254	N/A
6/30/2019	100,227	7,680	N/A	N/A	N/A
3/31/2019	98,655	9,250	870	13,242	N/A
12/31/2018	95,532	8,863	N/A	N/A	N/A
9/30/2018	92,018	8,721	N/A	N/A	N/A
6/30/2018	89,057	6,716	N/A	N/A	N/A
3/31/2018	90,744	8,039	6,034	16,481	N/A
12/31/2017	91,908	6,420	N/A	N/A	N/A
9/30/2017	95,055	10,083	N/A	N/A	N/A
6/30/2017	94,896	10,233	N/A	N/A	N/A
3/31/2017	90,794	9,160	N/A	6,574	N/A
12/31/2016	89,316	10,402	N/A	N/A	N/A
9/30/2016	81,749	7,508	N/A	N/A	N/A
6/30/2016	78,414	7,292	N/A	N/A	N/A
3/31/2016	75,732	7,021	N/A	3,448	N/A
12/31/2015	70,300	5,697	N/A	N/A	N/A
9/30/2015	69,530	5,141	N/A	N/A	N/A
6/30/2015	67,244	4,814	N/A	N/A	N/A
3/31/2015	65,561	4,753	N/A	4,817	N/A
12/31/2014	64,891	5,078	N/A	N/A	N/A
9/30/2014	63,983	6,092	N/A	N/A	N/A
6/30/2014	61,897	5,984	N/A	N/A	N/A
3/31/2014	59,450	5,423	N/A	8,537	N/A
12/31/2013	56,441	6,660	N/A	N/A	N/A
9/30/2013	54,241	6,627	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GLENMARK wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (6.7%).

Ertrag vs. Markt: GLENMARK wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: GLENMARK wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: GLENMARKDie Einnahmen des Unternehmens (10.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).

Hohe Wachstumseinnahmen: GLENMARKDie Einnahmen des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GLENMARKDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12 %).

Glenmark Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 9.7% to ₹1,056

Price target increased by 11% to ₹907

Price target increased by 12% to ₹689

Glenmark Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 13%

Recent updates

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Price target increased by 9.7% to ₹1,056

Full year 2024 earnings: EPS and revenues miss analyst expectations

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24

Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

Glenmark Pharmaceuticals Limited to Report Q4, 2024 Results on May 24, 2024

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Now 24% overvalued after recent price rise

Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) (GPL).

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Price target increased by 11% to ₹907

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2024 earnings released: ₹16.66 loss per share (vs ₹9.66 profit in 3Q 2023)

Glenmark Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Glenmark Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 10, 2023

Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-Morbidities

Glenmark Pharmaceuticals Receives ANDA Approval for Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg

Nirma Limited entered into a definitive agreement to acquire 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR 56.5 billion.

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals Divests 75% in GLS to Nirma

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited Announces Management Promotions

Upcoming dividend of ₹2.50 per share at 0.3% yield

Insufficient new directors

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

ChrysCapital Still in Race to Buy Controlling Stake in Glenmark Life Sciences

Price target increased by 12% to ₹689

First quarter 2024 earnings released: EPS: ₹5.31 (vs ₹6.82 in 1Q 2023)

Glenmark Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 11, 2023

Nirma, Sekhmet Pharmaventures Reportedly Vie for $731 Million Glenmark Life Stake

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Full year 2023 earnings released: EPS: ₹10.53 (vs ₹33.37 in FY 2022)

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-23

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Third quarter 2023 earnings released: EPS: ₹9.66 (vs ₹7.86 in 3Q 2022)

Glenmark Pharmaceuticals Limited Launches in India Unique I.V. Injection Formulation

Glenmark Pharmaceuticals Launches the Sacubitril + Valsartan Tablets in India for the Treatment of Heart Failure

Glenmark Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 10, 2023

Glenmark Pharmaceuticals Limited Receives Final Approval by United States Food & Drug Administration for Nicardipine Hydrochloride Capsules, 20 Mg and 30 Mg

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR3.1 billion.

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Glenmark Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

Glenmark Pharmaceuticals Limited to Launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, Having Comorbidities

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Glenmark Launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Upcoming dividend of ₹2.50 per share

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2022

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2022

First quarter 2023 earnings released: EPS: ₹6.82 (vs ₹10.86 in 1Q 2022)

Glenmark Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 10, 2022

Glenmark Pharmaceuticals Limited and SaNOtize Research and Development Corp. Announces Peer Reviewed Publication of Its Phase 3 Clinical Trials on Sanotize's Novel Nitric Oxide Nasal Spray for Covid-19 in Lancet Journal

Glenmark Pharmaceuticals Ltd. Launch's India's First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

Glenmark Pharmaceuticals Limited Launches Sitagliptin and its Fixed Dose Combinations for Adults with Type 2 Diabetes in India

Upcoming dividend of ₹2.50 per share

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Glenmark Pharmaceuticals Limited Launches Novel Fixed-Dose Combination Drug - Indacaterol + Mometasone for Patients Suffering from Uncontrolled Asthma, in India

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings